RecruitingACTRN12619000715178

Using Specialised Imaging to Differentiate Incidentally Found Renal Masses

Differentiating Renal Oncocytoma from Renal Cell Carcinoma Using Sestamibi Imaging


Sponsor

Thomas England

Enrollment

204 participants

Start Date

Oct 24, 2019

Study Type

Interventional

Conditions

Summary

What is the purpose of this study? The purpose is to investigate the possible role of specialised imaging called Sestamibi SEPC/CT in the diagnosis of renal masses. Who is it for? You are eligible to participate in this study if you are an adult that has had a renal mass detected and are scheduled to undergo a renal biopsy in the near future. Study details All willing and suitable participants will undergo specialised imaging involving a scan that takes approximately 45 minutes. The results of the imaging study will be compared with the results of the renal biopsy to be arranged as per normal by the patients urologist. If proven to be effective in its ability to differentiate renal oncocytomas from renal cell carcinoma the sestamibi imaging technique could be more frequently used in the standard investigation of renal masses detected on abdominal imaging. In doing so the number of invasive renal biopsies may decline.


Eligibility

Sex: Both males and femalesMin Age: 18 Yearss

Inclusion Criteria2

  • Patient with a renal mass detected with an imaging study where the radiological features of the mass make it hard to distinguish between renal cell carcinoma and renal oncocytoma.
  • Patient is scheduled to have a renal biopsy to determine the histopathological diagnosis of the mass in the near future.

Exclusion Criteria2

  • Pregnancy
  • Under 18 years of age

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

99m Tc-Sestamibi SPEC/CT is a nuclear imaging study used to investigate ischaemic heart disease and parathyroid nodules. Recently its use in renal mass imaging has increased as early research has show

99m Tc-Sestamibi SPEC/CT is a nuclear imaging study used to investigate ischaemic heart disease and parathyroid nodules. Recently its use in renal mass imaging has increased as early research has shown its ability to help differentiate benign renal oncocytomas from malignant renal cell carcinomas. Brand Name of 99m Tc-Sestamibi Tracer - Cardiolite Dose administered to patient is 925 MBq Effective radioactivity dose to patient is 5.32 mSv (with CT) 75-95 minutes must pass prior to imaging to enable effective renal uptake Imaging takes approximately 30 min


Locations(1)

WA, Australia

View Full Details on ANZCTR

For the most up-to-date information, visit the official listing.

Visit

ACTRN12619000715178